



**American  
Red Cross**

**HLA Services**  
180 Rustcraft Road  
Suite 115  
Dedham, MA 02026

(tel) 781-461-2148  
(fax) 781-461-2269

**Blood Services  
East Division**

ASHI# 10-1-MA-01-1  
Director: Neng Yu, M.D.  
CLIA# 22D0073830  
Director: Jorge Rios, M.D.

**ABH, QC 05302017**

MRN  
Registry Contract Typing

**HLA Report**

Patient: ABH, QC 05302017  
DOB:  
MRN:  
Category: Registry Contract Typing  
Report Date: 08/08/2017

Report to: VERGUEIRO, CARMEN  
ABH  
MARQUES DE ITU, 579  
SAO PAULO BRAZIL,

**HLA Typing**

<u>Name</u> <u>DOB/MRN</u> <u>LID</u> <u>Relation/ Source</u>	<u>Sample Dt</u> <u>Receive Dt</u> <u>Test Dt</u>	<u>A*</u>	<u>B*</u>	<u>C*</u>	<u>DRB1*</u>	<u>DRB345*</u>	<u>DQA1*</u>	<u>DQB1*</u>	<u>DPA1*</u>	<u>DPB1*</u>	<u>Haplo</u>
ABH, QC 05302017 /											
Patient /											
ABH, 103 /	05/23/2017 05/24/2017	02:01 68:02	07:06 15:16	07:02 16:01	01:02 03:02		01:01 04:01	05:01 04:02	02:01 03:01	105:01 131:01	
R602398-1 Unrelated Donor / Blood	05/30/2017					3*01:01					
ABH, 104 /	05/23/2017 05/24/2017	02:01	13:02 27:05	06:02 02:02	12:JV 04:02	3*01:01 4*01:03	01:05 03:01	05:01 03:02	01:03	02:01 18:01	
R602399-1 Unrelated Donor / Blood	05/26/2017										
ABH, 105 /	05/23/2017 05/24/2017	02:01	18:01 44:03	12:03 14:03	11:04 04:05	3*02:02 4*01:03	05:05 03:03	03:02 03:01	01:03	02:01 04:02	
R602400-1 Unrelated Donor / Blood	05/26/2017										
ABH, 106 /	05/23/2017 05/24/2017	02:05 29:02	41:01 44:03	07:01 16:01	03:01 10:01	3*01:01	05:01 01:05	02:01 05:01	02:01	01:01 17:01	
R602401-1 Unrelated Donor / Blood	05/26/2017										
ABH, 107 /	05/23/2017 05/24/2017	01:01 03:01	08:01 39:BMFM	07:01 12:03	16:01 03:01	5*02:02 3*01:01	01:02 05:01	05:02 02:01	01:03 02:01	02:01 10:01	
R602402-1 Unrelated Donor / Blood	05/26/2017										



**HLA Services**  
 180 Rustcraft Road  
 Suite 115  
 Dedham, MA 02026

(tel) 781-461-2148  
 (fax) 781-461-2269

**Blood Services  
 East Division**

ASHI# 10-1-MA-01-1  
 Director: Neng Yu, M.D.  
 CLIA# 22D0073830  
 Director: Jorge Rios, M.D.

**ABH, QC 05302017**

MRN  
 Registry Contract Typing

**HLA Report**

Allelic HLA typing was performed by PCR-SSOP, Sanger SBT, NGS. Low-Intermediate resolution HLA typing was performed by PCR-SSOP.

Code Translation:  
 JV - 01/10  
 BMFM - 39:01/39:01L

**Comments**

DPB1\*02:01, DPB1\*04:02 is ambiguous with DPB1\*105:01, DPB1\*416:01.

05/30/2017: ABH, 103 has a possible new HLA-DPA\*03 allele, identical to DPA\*03:01 at the protein level with a silent mutation at codon 204 (GTG to GTC).

HLA REPORT WITH THE THIRD FIELD:

ABH, 103: A\*02:01:01, A\*68:02:01, B\*07:06:01, B\*15:16:01, C\*07:02:01, 16:01:01, DRB1\*01:02:01, DRB1\*03:02:01, DRB3\*01:01:02, DQA1\*01:01:02, DQA1\*04:01:01, DQB1\*04:02:01, DQB1\*05:01:01, DPA1\*02:01:01, DPA1\* 03:01, DPB1\*105:01, DPB1\*131:01

ABH, 104: A\*02:01:01, B\*13:02:01, B\*27:05:02, C\*02:02:02, C\*06:02:01, DRB1\*04:02:01, DRB1\*12:01:01/12:10, DRB3\*01:01:02, DRB4\*01:03:01, DQA1\*01:05:01, DQA1\*03:01:01, DQB1\*03:02:01, DQB1\*05:01:01, DPA1\*01:03:01, DPB1\*02:01:02, DPB1\*18:01

ABH, 105: A\*02:01:01, B\*18:01:01, 44:03:01, C\*12:03:01, C\*14:03, DRB1\*04:05:01, DRB1\*11:04:01, DRB3\*02:02:01, DRB4\*01:03:01, DQA1\*03:03:01, DQA1\*05:05:01, DQB1\*03:01:01, DQB1\*03:02:01, DPA1\*01:03:01, DPB1\*02:01:02, DPB1\*04:02:01

ABH, 106: A\*02:05:01, A\*29:02:01, B\*41:01:01, B44:03:01, C\*07:01:01, C\*16:01:01, DRB1\*03:01:01, DRB1\*10:01:01, DRB3\*01:01:02, DQA1\*01:05:01, DQA1\*05:01:01, DQB1\*02:01:01, DQB1\*05:01:01, DPA1\*02:01:01, DPA1\*02:01:02, DPB1\*01:01:01, DPB1\*17:01

ABH, 107: A\*01:01:01, A\*03:01:01, B\*08:01:01, B\*39:01:01/01L, C\*07:01:01, C\*12:03:01, DRB1\*03:01:01, DRB1\*16:01:01, DQA1\*01:02:02, DQA1\*05:01:01, DQB1\*02:01:01, DQB1\*05:02:01, DPA1\*01:03:01, DPA1\*02:01:01, DPB1\*02:01:02, DPB1\*10:01:01

Electronically signed by  
 Marina Ohashi, CHS (ABHI) 08/08/2017  
 \_\_\_\_\_  
 Approved by Date  
 Director, Neng Yu, MD dip ABHI

Electronically submitted by  
 Paul Sibilias, MT (ASCP) 08/04/2017  
 \_\_\_\_\_  
 Reported by Date

This test was developed and its performance characteristics determined by this laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.